Louis Moore Bacon's ALNY Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 4,104 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $1.87 M, representing 0.03% of the portfolio. First purchased in 2015-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 21,985 shares. Largest reduction occurred in Q4 2023, reducing 17,350 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2015 | +5,500 | New Buy | 5,500 | $104.36 |
| Q2 2015 | -5,500 | Sold Out | 0 | $0.00 |
| Q3 2022 | +21,247 | New Buy | 21,247 | $200.17 |
| Q4 2022 | -11,247 | Reduce 52.93% | 10,000 | $237.65 |
| Q1 2023 | -10,000 | Sold Out | 0 | $0.00 |
| Q3 2023 | +21,985 | New Buy | 21,985 | $177.10 |
| Q4 2023 | -17,350 | Reduce 78.92% | 4,635 | $191.41 |
| Q1 2024 | -4,635 | Sold Out | 0 | $0.00 |
| Q3 2025 | +4,104 | New Buy | 4,104 | $456.00 |
Louis Moore Bacon's Alnylam Pharmaceuticals Investment FAQs
Louis Moore Bacon first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q1 2015, acquiring 5,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Alnylam Pharmaceuticals, Inc. (ALNY) for 9 quarters since Q1 2015.
Louis Moore Bacon's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2023, adding 21,985 shares worth $3.89 M.
According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 4,104 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $1.87 M.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 21,985 shares, as reported at the end of Q3 2023.